Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Depreciation and Depletion: 2019-2025

Historic Depreciation and Depletion for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $2.1 million.

  • Kymera Therapeutics' Depreciation and Depletion rose 5.00% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 17.46%. This contributed to the annual value of $7.4 million for FY2024, which is 105.56% up from last year.
  • Kymera Therapeutics' Depreciation and Depletion amounted to $2.1 million in Q3 2025, which was up 23.53% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Depreciation and Depletion ranged from a high of $2.4 million in Q4 2021 and a low of $700 during Q3 2021.
  • In the last 3 years, Kymera Therapeutics' Depreciation and Depletion had a median value of $1.6 million in 2025 and averaged $1.5 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first crashed by 99.86% in 2021, then skyrocketed by 114,185.71% in 2022.
  • Over the past 5 years, Kymera Therapeutics' Depreciation and Depletion (Quarterly) stood at $2.4 million in 2021, then plummeted by 66.64% to $800,000 in 2022, then climbed by 12.50% to $900,000 in 2023, then skyrocketed by 122.22% to $2.0 million in 2024, then climbed by 5.00% to $2.1 million in 2025.
  • Its Depreciation and Depletion was $2.1 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.6 million in Q1 2025.